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Derangement of Ras-Guanine Nucleotide-Releasing
Factor 1 (Ras-GRF1) and Extracellular
Signal-Regulated Kinase (ERK) Dependent Striatal
Plasticity in L-DOPA-Induced Dyskinesia
Milica Cerovic, Vincenza Bagetta, Valentina Pendolino, Veronica Ghiglieri, Stefania Fasano,
Ilaria Morella, Neil Hardingham, Andreas Heuer, Alessandro Papale, Francesca Marchisella,
Carmela Giampà, Paolo Calabresi, Barbara Picconi, and Riccardo Brambilla
Background: Bidirectional long-term plasticity at the corticostriatal synapse has been proposed as a central cellular mechanism
governing dopamine-mediated behavioral adaptations in the basal ganglia system. Balanced activity of medium spiny neurons (MSNs) in
the direct and the indirect pathways is essential for normal striatal function. This balance is disrupted in Parkinson’s disease and in L-3,4-
dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID), a common motor complication of current pharmacotherapy of Parkinson’s
disease.
Methods: Electrophysiological recordings were performed in mouse cortico-striatal slice preparation. Synaptic plasticity, such as long-
term potentiation (LTP) and depotentiation, was investigated. Speciﬁc pharmacological inhibitors or genetic manipulations were used to
modulate the Ras-extracellular signal-regulated kinase (Ras-ERK) pathway, a signal transduction cascade implicated in behavioral
plasticity, and synaptic activity in different subpopulations of striatal neurons was measured.
Results: We found that the Ras-ERK pathway, is not only essential for long-term potentiation induced with a high frequency stimulation
protocol (HFS-LTP) in the dorsal striatum, but also for its reversal, synaptic depotentiation. Ablation of Ras-guanine nucleotide-releasing
factor 1 (Ras-GRF1), a neuronal activator of Ras proteins, causes a speciﬁc loss of HFS-LTP in the medium spiny neurons in the direct
pathway without affecting LTP in the indirect pathway. Analysis of LTP in animals with unilateral 6-hydroxydopamine lesions (6-OHDA)
rendered dyskinetic with chronic L-DOPA treatment reveals a complex, Ras-GRF1 and pathway-independent, apparently stochastic
involvement of ERK.
Conclusions: These data not only demonstrate a central role for Ras-ERK signaling in striatal LTP, depotentiation, and LTP restored after
L-DOPA treatment but also disclose multifaceted synaptic adaptations occurring in response to dopaminergic denervation and pulsatile
administration of L-DOPA.
Key Words: Depotentiation, L-DOPA-induced dyskinesia, long-term
potentiation (LTP), long-term depression (LTD), Ras-ERK signaling,
Ras-GRF1, striatum
Changes in the synaptic efﬁcacy at corticostriatal synapsesare believed to be central not only to the regulation ofnormal cellular functions of the basal ganglia system but
also in pathological conditions such as Parkinson’s disease and
motor complications associated with prolonged dopamine (DA)
replacement pharmacotherapy using L-3,4-dihydroxyphenylala-
nine (L-DOPA) (L-DOPA-induced dyskinesia [LID]) (1–3). These
behavioral alterations, most frequently studied in the dorsal
striatum, have been correlated to altered bidirectional synaptic
plasticity—long-term potentiation (LTP), long-term depression
(LTD), and depotentiation. Bidirectional synaptic plasticity (LTP
and LTD) can be induced in most medium spiny neurons (MSNs),
the largest neuronal population of the striatum, by means of
high-frequency stimulation (HFS) (100 Hz) of excitatory afferents
(1,4–6).
The MSNs are believed to consist of two distinct populations,
the striatonigral (direct) pathway neurons and the striatopallidal
(indirect) pathway cells, which predominantly express DA D1-like
and D2-like receptors, respectively. Corticostriatal synaptic plasti-
city is impaired in MSNs of DA-depleted experimental models,
such as the unilateral 6-hydroxydopamine (6-OHDA)-lesion sys-
tem (6), and is restored by long-term L-DOPA administration (7).
More recent evidence suggests that in DA-denervated animals
both types of MSNs undergo a reduction in spine density and a
corresponding increase in neuronal excitability, a condition
partially reverted by L-DOPA treatment (8). Synaptic alterations
have been speciﬁcally linked to abnormal involuntary movements
(AIMs), the rodent correlate of LID. First, striatal synapses from
parkinsonian dyskinetic rats fail to depotentiate, a condition
normally obtained when low-frequency stimulation (LFS) protocol
is applied after the induction of HFS-induced LTP (7,9). Second,
HFS-induced LTD cannot be restored in dyskinetic animals unless
phosphodiesterase inhibitors are administered (10).
The Ras-extracellular signal-regulated kinase (Ras-ERK) cascade
is an evolutionarily conserved signaling cassette implicated in
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several important cellular responses, including memory forma-
tion, synaptic plasticity, and behavioral adaptations in the central
nervous system as well as in cell proliferation and survival in most
cell types (11–13). In the striatum, the Ras-ERK pathway has been
shown to control instrumental learning and memory. Additionally,
Ras-ERK signaling modulates responses to drugs of abuse and to
chronic administration of L-DOPA in experimental models of LID
(14–17). To date, the role of Ras-ERK in corticostriatal plasticity has
been assessed only preliminarily under some pathological con-
ditions but not in its normal or in DA-depleted state (18,19). In the
present study, we show that Ras-ERK signaling is crucial for the
induction of HFS-induced LTP and depotentiation at excitatory
corticostriatal synapses but that it is not required for HFS-induced
LTD. We found that Ras-guanine nucleotide-releasing factor 1
(Ras-GRF1) a brain-speciﬁc upstream component of the ERK
pathway, modulates HFS-induced LTP selectively in the direct
striatal pathway, suggesting that other factors may control ERK
signaling in the indirect pathway. In DA-denervated synapses
after prolonged L-DOPA treatment, LTP requires ERK signaling in
a complex, Ras-GRF1-independent and pathway-independent
manner, in contrast to HFS-LTP in the physiological state. Finally,
Ras-GRF1 and ERK signaling in synapses from dyskinetic mice
impedes rather than facilitates depotentiation of LTP restored by
L-DOPA treatment, conﬁrming a derangement of ERK-mediated
mechanisms in this neurophysiological correlate of LID.
Methods and Materials
A detailed description of all methods and materials can be found
in Supplement 1. Generation of Ras-GRF1 knockout (KO) mice has
been previously described (20–22). Bac-enhanced green ﬂuorescent
protein (EGFP) mice (M4-EGFP and A2A-EGFP) were originally
generated by the Gene Expression Nervous System Atlas program
at Rockefeller University (www.gensat.org) (23). For lesion and LID
studies, mice were injected with 6-OHDA into the right medial
forebrain bundle, and AIMs were induced as previously described
(22). Brain slices and solutions for electrophysiology were prepared
as described elsewhere (7,24). Brieﬂy, extracellular ﬁeld recordings of
glutamate-driven population spikes and intracellular whole-cell
Figure 1. Synaptic responses and long-term plasticity in striatal slices treated with the MEK inhibitor U0126. (A) Left panel shows HFS-LTD was not
signiﬁcantly affected by bathing before incubation (10–20 min) with U0126 (5 mmol/L) (DMSO, n ¼ 6; U0126, n ¼ 6; time effect, two-way analysis of
variance, p ! .001). Right panel shows ﬁeld amplitudes as % of baseline 60 min after LTD induction were not affected by treatment with U0126 (DMSO ¼
69.6%" 2.5% vs. U0126 ¼ 74.0%" 3.5%, Student t test, p # .05). (B) Left panel shows HFS-LTP was blocked by pretreatment with 5 mmol/L U0126 (DMSO,
n ¼ 7; U0126, n ¼ 7; treatment effect, two-way analysis of variance, p ! .0001). Right panel shows ﬁeld amplitudes as % of baseline 60 min after LTP
induction indicate a signiﬁcant effect of U0126 treatment (DMSO ¼ 166% " 10.2% vs. U0126 ¼ 102.6% " 3.5%, Student t test, ***p ! .0001. (C) U0126
(5 mmol/L) does not affect LTP maintenance when applied 20 min after HFS induction (LTP before U0126 ¼ 178% " 16.1% vs. after U0126 ¼ 180.5% "
16.3%, n ¼ 4, Student t test, p # .05). Insets show representative traces before and after HFS in untreated and U0126-treated slices from naïve mice. DMSO,
dimethyl sulfoxide; HFS, high-frequency stimulation; LTP, long-term potentiation; MEK, mitogen-activated protein kinase kinase.
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patch recordings were obtained in the dorsolateral striatum where
stimuli were delivered via bipolar stimulating electrodes.
Induction of LTD and LTP was accomplished with HFS
consisting of three to four trains at 100 Hz of 1–3 sec duration
with 20-sec intratrain intervals. This protocol was used in the
presence of 1.2 mmol/L Mg2$ in recording solution to obtain LTD;
LTP was induced in Mg2$-free solution. To depotentiate pre-
viously induced LTP, LFS for 10 min at 2 Hz was delivered. For
immunoﬂuorescence and immunohistochemistry studies, slices
were ﬁrst stimulated with HFS to induce LTP and 10 min later
were ﬁxed with 4% paraformaldehyde. Control slices were
perfused 20–30 min with Mg2$-free solution before ﬁxing. These
slices were resliced into thinner sections and processed for
immunohistochemistry and immunoﬂuorescence according to
published procedures (22,25).
Results
ERK Signaling Is Necessary for HFS-LTP at Corticostriatal
Synapse
The Ras-ERK signaling pathway in the dorsal portion of the
striatum is abnormally activated in response to both drugs of
abuse and L-DOPA (15,26). Hyperactivation of this signaling
cascade may represent a key pathological factor for both drug
addiction and LID, two conditions relying on abnormal DA-
mediated adaptations in the basal ganglia system. In particular,
we showed more recently that Ras-GRF1, a neuronal speciﬁc
guanosine diphosphate/guanosine triphosphate (GDP/GTP) Ras-
exchange factor, plays a crucial role in the regulation of ERK-
mediated cellular and behavioral responses to psychostimulants
by sensing and integrating DA and glutamate signaling in the
striatum. In addition, Ras-GRF1 inhibition, both in murine and in
nonhuman primate models of LID, signiﬁcantly improves the
behavioral symptoms linked to repeated L-DOPA administration
(21,22). To identify the synaptic correlates of the observed
behavioral responses in MSNs, we investigated the role of Ras-
GRF1 and ERK signaling in long-term plasticity at the cortico-
striatal synapse.
We performed extracellular ﬁeld recordings of population
spike responses in slices obtained from wild-type (WT) mice
and exposed to the mitogen-activated protein kinase kinase
(MEK) inhibitor U0126 (5 mmol/L), which blocks ERK signaling.
This treatment did not affect basal synaptic responses that were
consistent within a whole range of stimulus intensities (Figure
S1A in Supplement 1). When HFS was delivered in physiological
Mg2$ concentration, robust LTD was induced in both vehicle and
U0126-treated slices (Figure 1A). Next, we examined corticostriatal
LTP. To this purpose, Mg2$ was removed from the extracellular
medium, promoting stronger activation of glutamate N-methyl-D-
aspartate receptors (1,4–6). Under these experimental conditions,
HFS-LTP was completely abolished by pretreatment with 5 mmol/L
U0126 (Figure 1B, left panel). Analysis of the posttetanic mean
amplitudes (60 min) further conﬁrmed the effect of U0126
treatment (Figure 1B, right panel). We obtained similar results
using intracellular recordings where LTP induction was abolished
by U0126 treatment in all recorded cells (Figure S1B in
Supplement 1).
To test whether ERK is implicated in both LTP maintenance
and depotentiation, U0126 was applied 20 min after tetanus in
ﬁeld recordings. This treatment did not affect LTP (Figure 1C).
However, pretreatment of potentiated synapses with this MEK
inhibitor did prevent depotentiation after LFS (Figure 2).
Altogether, these data indicate that ERK signaling is necessary
not only for the induction of HFS-LTP in the dorsal striatum but
also for synaptic depotentiation. However, ERK is not required for
LTP maintenance, HFS-LTD and basal synaptic transmission.
Ras-GRF1 Controls HFS-LTP in Striatonigral Pathway
Our data suggest a speciﬁc role for ERK signaling in the induction
of HFS-LTP but do not implicate Ras-GRF1 in striatal synaptic
plasticity. To address this issue, we performed electrophysiological
recordings using intracellular sharp electrodes in corticostriatal slices
from WT and Ras-GRF1 KO mice (4,5,20). A normal HFS-LTD could be
induced in both WT and mutant mice (Figure 3A, left panel). Analysis
of the 40-min posttetanic mean amplitudes conﬁrms the lack of
genotype effect (Figure 3A, right panel). However, although HFS-LTP
could be reliably induced in WT mice, this form of plasticity was
present in "50% of the striatal MSNs recorded from Ras-GRF1 KO
mice (Figure 3B, left panel). Comparison of the 40-min posttetanic
mean amplitudes conﬁrms that only one subpopulation of Ras-GRF1
KO MSNs lacked LTP (Figure 3B, right panel). These data indicate that
ERK signaling in the dorsal striatum is necessary for HFS-LTP but not
Figure 2. Depotentiation is prevented by application of U0126. LFS–induced
depotentiation was blocked by application of 5 mmol/L U0126 (U0126, before
vs. after LFS, Student t test, p# .05, n ¼ 6; CTRL, before vs. after LFS, Student
t test, ###p ! .0001, n ¼ 6; CTRL vs. U0126, two-way analysis of variance,
p ! .0001; post hoc Bonferroni, **p ! .001, ***p ! .0001). Inset shows repre-
sentative traces before HFS, after HFS, and on LFS in naïve and U0126-treated
slices. CTRL, control; EPSP, excitatory postsynaptic potential; HFS, high-
frequency stimulation; LFS, low-frequency stimulation.
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for HFS-LTD and that Ras-GRF1 is likely to play a role only in a
speciﬁc subset of MSNs.
Because we previously established that the Ras-GRF1 is equally
expressed in both striatonigral and striatopallidal MSNs, the
pathway-speciﬁc involvement of Ras-GRF1 in LTP is likely due to
its speciﬁc engagement by a subclass of these striatal cells (22). To
clarify which subpopulation of MSNs is affected by the loss of Ras-
GRF1, we took advantage of two types of bacterial artiﬁcial
chromosome transgenic mice expressing enhanced green ﬂuores-
cent protein (EGFP) speciﬁcally in striatonigral (M4-EGFP mice) or
striatopallidal (A2A-EGFP mice) MSNs (23). To study the role of Ras-
GRF1 in the two different subpopulations of MSNs, we combined
these bacterial artiﬁcial chromosome transgenic mutants with Ras-
GRF1 KO mice to obtain double mutants (M4-EGFP/Ras-GRF1 KO
and A2A-EGFP/Ras-GRF1 KO). We ﬁrst performed whole-cell patch
clamp recordings from M4-EGFP and A2A-EGFP single transgenic
mice to ensure that LTP could be reliably induced in EGFP-positive
and EGFP-negative cells in both transgenic lines. We were able to
induce LTP, with similar amplitude and time course, in both
ﬂuorescent and nonﬂuorescent MSNs from M4-EGFP mice (Figure
S2A in Supplement 1). Similarly, A2A-EGFP mice also showed LTP in
both cell populations (Figure S2B in Supplement 1). However,
when we subsequently performed recordings in slices obtained
from M4-EGFP/Ras-GRF1 KO double mutants, LTP could be induced
only in indirect pathway MSNs (iMSNs) (Figure 4A). As a further
conﬁrmation that Ras-GRF1 is essential for LTP in direct pathway
MSNs (dMSNs), we also performed recordings from A2A-EGFP/Ras-
GRF1 KO double mutants (Figure 4B). This ﬁnding provides
evidence for the selective involvement of Ras-GRF1 in the control
of HFS-LTP in the direct striatal pathway. The residual LTP in naïve
Ras-GRF1 KO slices was completely blocked by U0126 treatment,
conﬁrming that LTP in the indirect pathway is ERK, but not Ras-
GRF1, dependent (Figure S2C in Supplement 1). When the experi-
ments were performed by measuring extracellular ﬁeld responses,
we found that the magnitude of LTP in Ras-GRF1 KO slices was
signiﬁcantly smaller compared with WT slices as a result of the
selective contribution of synaptic potentiation in the iMSNs (Figure
S2C in Supplement 1).
Figure 3. Electrophysiological analysis of the corticostriatal synaptic plasticity recorded from WT and Ras-GRF1 KO mice. (A) Left panel shows HFS protocol
induced a normal long-term depression in both WT and mutant mice (WT, n ¼ 8; Ras-GRF1 KO, n ¼ 9; time effect, two-way analysis of variance, p ! .001).
Bar diagram in the right panel shows the EPSP amplitude as % of control, measured at 40 min after tetanus, both in WT and in mutant mice (WT ¼ 60.3% "
4.3% vs. Ras-GRF1 KO ¼ 58.3% " 6.1%, Student t test, p # .05). (B) Left panel shows LTP was induced only in half of the striatal MSNs recorded from Ras-
GRF1 KO mice (Ras-GRF1 KO LTP MSNs, n ¼ 8 vs. Ras-GRF1 KO No LTP MSNs, n ¼ 9, two-way analysis of variance, p ! .001; post hoc Bonferroni, ***p ! .001;
WT, n ¼ 5 vs. Ras-GRF1 KO No LTP MSNs, post hoc Bonferroni, ##p ! .01, ###p ! .001). Bar diagram in the right panel shows the mean EPSP amplitudes as %
of control for all three cell populations (WT ¼ 143.1% " 4.5%, Ras-GRF1 KO LTP ¼ 160.0% " 15.8%, Ras-GRF1 KO No LTP ¼ 95.2% " 4.6%; WT vs. KO No
LTP, one-way analysis of variance, ##p ! .01; KO LTP vs. KO No LTP, one-way analysis of variance, ***p ! .001). Sample traces of EPSP amplitudes before and
after HFS in WT and Ras-GRF1 KO mice are shown on the right of each panel. EPSP, excitatory postsynaptic potential; HFS, high-frequency stimulation;
LTP, long-term potentiation; KO, knockout; MSN, medium spiny neuron; Ras-GRF1, Ras-guanine nucleotide-releasing factor1; WT, wild-type.
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To gain direct information about cell signaling processes
during LTP induction, we measured the phosphorylation levels
of ERK1/2 in acute corticostriatal slices stimulated with the
HFS-LTP protocol. The ERK phosphorylation (pERK) levels were
signiﬁcantly higher in stimulated slices compared with control
slices, and U0126 treatment fully prevented this increase (Figure
S3A in Supplement 1).
To distinguish between downstream effect of ERK in the two
striatal pathways, we also measured the phosphorylation levels of
ribosomal protein S6 (p-S6) on Ser235/236, a cytoplasmic target of
ERK1/2 activity, as well as one of its nuclear targets, histone H3
(p-H3), by using immunoﬂuorescence techniques (25). Similar to
pERK1/2, total p-S6 levels were signiﬁcantly higher in stimulated slices
compared with control slices, and this stimulation was shown to be
entirely ERK dependent because pretreatment with U0126 com-
pletely abolished the signal (Figure S4A in Supplement 1). However,
we observed differences in the ability of HFS-LTP to induce S6
phosphorylation in the two pathways. Basal levels of p-S6 appeared
to be higher in the indirect pathway compared with the direct
pathway, whereas the stimulation effect was similar (Figure S4B,C in
Supplement 1). Induction of p-S6 was totally blocked in Ras-GRF1 KO
slices but only in the direct pathway (Figure S4B,C in Supplement 1).
When p-H3 was monitored, we found a similar scenario, with a
higher activation in the indirect pathway than in the direct one, with
both completely inhibited by U0126 (Figure S5 in Supplement 1).
These data conﬁrm that ERK activation is necessary for HFS-LTP in
both pathways and that Ras-GRF1 controls ERK1/2 signaling only in
the direct pathway, further supporting the observation that in Ras-
GRF1 KO slices only the striatonigral LTP is impaired.
Ras-GRF1 and ERK Signaling Control DA-Mediated
Adaptations in the Murine Model of LID
Parkinson’s disease is a neurodegenerative disorder charac-
terized by a slow, inexorable loss of substantia nigra pars
compacta dopaminergic neurons and by an ensuing depletion
of DA input to the striatum. The most effective treatment for
Parkinson’s disease is DA replacement therapy, using the DA
precursor L-DOPA, but prolonged use of L-DOPA is associated
with complications including motor ﬂuctuations and LID, which
can limit treatment over time (16,27–29). Considering the central
role played by Ras-GRF1 and ERK signaling in HFS-LTP, we
assessed the possibility that this intracellular pathway may also
be implicated in synaptic alterations in response to both DA
depletion and replacement with L-DOPA. We ﬁrst generated a
unilateral 6-OHDA-lesion model of Parkinson’s disease by inject-
ing the neurotoxin into the right medial forebrain bundle of both
Ras-GRF1 KO mice and control mice (littermates). We measured
spontaneous ipsilateral rotations 2 weeks after surgery as an
efﬁcacy index of the lesion. The rotational behavior was similar in
the two genotypes (Figure S6A in Supplement 1), suggesting an
equivalent sensitivity to the neurotoxic damage. To elicit axial,
limb, and orolingual AIMs, a validated model of LID in mice, we
administered an ascending dose regimen of L-DOPA (3 mg/kg, 6
mg/kg, 12 mg/kg daily) to both 6-OHDA-lesion WT and Ras-GRF1
mutant mice for 9 consecutive days (22). Daily scoring of AIMs,
from day 1–8, revealed gradual development of dyskinetic
symptoms in both genotypes, which affected the trunk, limb,
and orolingual regions on the side of the body contralateral to
the lesion. However, AIMs scores were signiﬁcantly reduced in
Ras-GRF1 KO mice compared with their littermate controls (Figure
S6B in Supplement 1). These results are consistent with our
previous data showing that the absence of Ras-GRF1 strongly
attenuates LID induction in mice (22).
After 6-OHDA lesioning, all MSNs recorded from either WT
mice or Ras-GRF1 KO mice lost the ability to show LTP, an
expected consequence of DA denervation (Figure S6C in
Supplement 1) (4,6). L-DOPA treatment has been shown to rescue
LTP in DA-denervated rats, but, concomitantly with the
Figure 4. HFS-LTP is absent in the dMSNs from Ras-GRF1 KO mice. (A) Left panel shows in mice expressing EGFP in striatonigral MSNs (M4-EGFP)/Ras-
GRF1 KO mice long-term potentiation was blocked in the direct pathway (dMSNs, n ¼ 5 vs. iMSNs, n ¼ 5, two-way analysis of variance, p ! .001; post hoc
Bonferroni, **p ! .001, ***p ! .0001). Right panel shows EPSP amplitudes 40 min after HFS as % of baseline (dMSNs ¼ 93.1% " 8.7% vs. iMSNs ¼ 173.1%
" 22.3%, Student t test, ***p ! .0001). (B) Left panel shows HFS-LTP was blocked in the dMSNs from mice expressing EGFP in striatopallidal MSNs (A2A-
EGFP)/Ras-GRF1 KO mice (dMSNs, n ¼ 6 vs. iMSNs, n ¼ 4, two-way analysis of variance, p ! .0001; post hoc Bonferroni, ***p ! .0001). Right panel shows
EPSP amplitudes 40 min after HFS as % of baseline (dMSNs ¼ 89.4% " 6.1% vs. iMSNs ¼ 174.7% " 24.2%, Student t test, ***p ! .0001). Insets are sample
traces of EPSP amplitudes before and after HFS in M4-EGFP/Ras-GRF1 KO and A2A-EGFP/Ras-GRF1 KO mice. dMSN, direct pathway MSN; EGFP, enhanced
green ﬂuorescent protein; EPSP, excitatory postsynaptic potential; HFS, high-frequency stimulation; iMSN, indirect pathway MSN; LTP, long-term
potentiation; KO, knockout; MSN, medium spiny neuron; Ras-GRF1, Ras-guanine nucleotide-releasing factor1.
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development of AIMs, depotentiation is occluded (7). We next
examined the induction of LTP and its reversal by LFS in slices
from Ras-GRF1 KO mice and WT littermates with 6-OHDA lesions
and administered long-term L-DOPA treatment. The MSNs
intracellularly recorded from the mildly dyskinetic Ras-GRF1 KO
mice displayed normal LTP after HFS and a signiﬁcant depot-
entiation of the synaptic activity after LFS, suggesting that
corticostriatal plasticity parallels the low dyskinetic proﬁle of
these mutants. Conversely, although LTP was normal in the
highly dyskinetic WT control mice, depotentiation was abolished
(Figure 5A).
Although both Ras-GRF1 KO and WT mice showed HFS-LTP in
response to chronic L-DOPA administration, LFS (intracellular
recording) produced depotentiation only in Ras-GRF1 KO mice,
which showed fewer dyskinetic symptoms compared with WT
mice. These data clearly indicate that, in contrast to depotentiation
in naïve slices, which requires ERK signaling, in dyskinetic slices
synaptic depotentiation is facilitated by ERK blockade through Ras-
GRF1 ablation. To support this evidence by a direct pharmaco-
logical inhibition of ERK, we treated slices from WT dyskinetic mice
with U0126 10 min before LFS in ﬁeld recordings. This treatment
restored depotentiation (Figure 5B), conﬁrming that in the
dyskinetic condition ERK signaling is part of the mechanism
occluding depotentiation, in contrast to the naïve condition, in
which ERK instead plays a facilitating role.
The observation that LTP not only was restored after L-DOPA
treatment in the Ras-GRF1 mutants in the indirect pathway but also
established de novo in the direct pathway indicates that profound
cellular adaptations occur in denervated animals subjected to
chronic L-DOPA administration. In particular, these data suggest
that ERK signaling through Ras-GRF1 may no longer be necessary for
LTP induction in L-DOPA-treated mice. To test this hypothesis, we
pretreated striatal slices from dyskinetic animals with U0126 (5 μmol/
L). Unexpectedly, we detected two distinct but equally represented
cell populations: one in which U0126 administration blocked the
induction of LTP and the other in which the drug did not have any
effect on this form of plasticity (Figure 6A). To exclude the possibility
that ERK signaling sensitivity to pharmacologic manipulation was
affected by the development of dyskinesia, we repeated the
experiment using a higher dose of U0126 (20 μmol/L). Under these
experimental conditions, we obtained the same pattern of LTP
induction as with the 5-μmol/L dose (Figure 6B).
Altogether, this evidence indicates that "50% of MSNs can
still manifest LTP even in the absence of ERK signaling. One
obvious possibility was that the observed segregation in two
populations could be related to the two functional pathways, the
striatonigral and the striatopallidal. To test this hypothesis, we
recorded from EGFP-positive cells obtained from A2A-EGFP and
M4-EGFP transgenic dyskinetic mice. As shown in Figure 6C–D,
the same distribution pattern was evident, with EGFP-positive
cells showing either LTP or no LTP in the presence of U0126 (5
μmol/L), roughly following a 50:50 ratio.
The scenario emerging from our data on L-DOPA-treated
animals is complex. On one hand, Ras-GRF1 is not required for
LTP in the direct pathway of L-DOPA-treated parkinsonian mice,
in contrast to what is observed in the naïve animals, in which loss
of Ras-GRF1 completely blocks LTP in the striatonigral MSNs. On
the other hand, ERK signaling is still necessary to induce LTP after
chronic L-DOPA administration but in a pathway-independent,
apparently stochastic manner.
Discussion
The Ras-ERK signaling pathway is activated in MSNs by a
combined engagement of DA and glutamate receptors, making it
a suitable candidate for having a regulatory role in striatal
synaptic plasticity (14–16). It is now well established that distinct
chemical stimuli are able to activate ERK signaling in speciﬁc MSN
subpopulations. For example, psychostimulants in intact animals
and L-DOPA in denervated animals selectively activate the ERK
cascade in MSNs of the direct pathway (30,31). The present study
provides initial evidence of a complex role of ERK-dependent and
Ras-GRF1-dependent signaling in corticostriatal plasticity, high-
lighting profound differences between synaptic mechanisms
in naïve slices and DA-depleted preparations obtained from
L-DOPA-treated dyskinetic animals.
First, ERK in naïve slices is vital for LTP induction, but not for its
maintenance, in both striatal pathways. Second, the mechanism
of ERK activation in response to HFS is distinctly different in the
two cell types. In striatonigral MSNs, LTP is Ras-GRF1 dependent,
whereas LTP is Ras-GRF1 independent in striatopallidal MSNs. This
evidence is unexpected because we previously demonstrated
that Ras-GRF1 is expressed in both MSN subpopulations (22).
Figure 5. Depotentiation in dyskinetic mice can be restored either by the ablation of Ras-GRF1 or by the speciﬁc MEK inhibitor U0126. (A) L-DOPA-treated
Ras-GRF1 KO mice showed a normal LTP after HFS. The subsequent LFS protocol induced a signiﬁcant depotentiation in all MSNs recorded (before LFS vs.
after LFS dyskinetic Ras-GRF1 KO, Student t test, p ! .0001; dyskinetic WT, n ¼ 4 vs. dyskinetic Ras-GRF1 KO, n ¼ 7, post hoc Bonferroni, *p ! .05). (B) In
slices from dyskinetic WT mice when U0126 (5 mmol/L) was applied 10 min before LFS, a signiﬁcant depotentiation was observed (before vs. after LFS
dyskinetic WT $ U0126, Student t test, p ! .05; dyskinetic WT, n ¼ 5 vs. dyskinetic WT $ U0126, n ¼ 6, post hoc Bonferroni, *p ! .05). EPSP, excitatory
postsynaptic potential; HFS, high-frequency stimulation; LTP, long-term potentiation; KO, knockout; MEK, mitogen-activated protein kinase kinase; MSN,
medium spiny neuron; Ras-GRF1, Ras-guanine nucleotide-releasing factor1; WT, wild-type.
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One possibility is that Ras-GRF1 loss in the indirect pathway is
either compensated by other Ras-speciﬁc exchange factors (e.g.,
Ras-GRF2 or CalDGEFI/II) or that DARPP-32 activation is sufﬁcient
to increase ERK activity by acting downstream in the pathway,
effectively bypassing Ras requirement. We also provided bio-
chemical evidence supporting the idea that ERK activation in
response to HFS occurs in both striatal pathways, although Ras-
GRF1 is necessary only in dMSNs. The fact that ERK signaling
activity is stronger in the iMSNs may be due to the higher
excitability of these neurons compared with the dMSNs, as
previously shown (24,32,33).
Third, we observed that ERK signaling is also necessary for the
reversal of HFS-LTP (i.e., synaptic depotentiation), a still poorly
understood phenomenon, often associated with LTD and the
action of protein phosphatases (7,34). Fourth, our data support
the idea that depotentiation and HFS-LTD in the striatum are
distinct processes because the latter does not require ERK
signaling. To support this evidence, we have provided data both
using a chemical inhibitor of ERK signaling and using Ras-GRF1
mutant mice. In both cases, HFS-LTD is spared, and depot-
entiation is blocked.
This study demonstrates that in DA-denervated and dyskinetic
animals, corticostriatal plasticity dependent on L-DOPA is pro-
foundly altered. First, although L-DOPA causes less LID in Ras-
GRF1 mutants, it restores HFS-LTP in both direct pathway and
indirect pathway MSNs. Because LTP in the direct pathway is
Figure 6. Effects of U0126 on LTP in dyskinetic mice. (A) Left panel shows LTP could be induced in half of MSNs recorded in slices from dyskinetic mice
pretreated with U0126 (5 mmol/L) (dyskinetic mice$ vehicle, n¼ 8 vs. dyskinetic mice$ U0126 No LTP MSNs, n¼ 6, post hoc Bonferroni, ###p! .001; dyskinetic
mice $ U0126 LTP MSNs, n ¼ 6 vs. dyskinetic mice $ U0126 No LTP MSNs, n ¼ 6, post hoc Bonferroni, ***p ! .001). Bar diagram in the right panel shows the
mean of EPSP amplitude as % of control for all three cell populations (CTRL¼ 160%" 7.9%, No LTP MSNs ¼ 92.2%" 6.5%, LTP MSNs ¼ 170.1%" 14.8%, one-
way analysis of variance, ###p ! .001, ***p ! .001). (B) Left panel shows the application of 20 mmol/L U0126 prevented LTP induction in half of the recorded
MSNs from dyskinetic WT mice (LTP MSNs, n ¼ 6 vs. No LTP MSNs, n ¼ 7, two-way analysis of variance, p ! .001). Histogram in the right panel shows the mean
EPSP amplitude as % of control 30 min after HFS for both cell populations (No LTP MSNs ¼ 111.0% " 5.2% vs. LTP MSNs ¼ 157.0% " 3.2%, Student t test,
***p! .001). (C) Left panel shows in dyskinetic mice expressing EGFP in dMSNs (M4-EGFP) the application of 5 mmol of U0126 prevented LTP induction in half of
the ﬂuorescent dMSNs (LTP M4-EGFP MSNs, n ¼ 4 vs. No LTP M4-EGFP MSNs, n ¼ 4, post hoc Bonferroni, ***p ! .001). Bar diagram in the right panel shows the
mean EPSP amplitude as % of control 30 min after HFS for both cell populations (LTP M4-EGFP MSNs ¼ 159.2%" 12.9% vs. No LTP M4-EGFP MSNs ¼ 85.29%"
15.5%, Student t test, ***p ! .001). (D) Left panel shows the application of 5 mmol/L U0126 prevented LTP induction in roughly the same percentage of MSNs
recorded from dyskinetic mice expressing EGFP in iMSNs (A2A-EGFP) (LTP A2A-EGFP MSNs, n ¼ 3 vs. No LTP A2A-EGFP MSNs, n ¼ 3, two-way analysis of
variance, p ! .0001, post hoc Bonferroni, ***p ! .001). Histogram in the right panel shows the mean EPSP amplitude as % of control 30 min after HFS for both
cell populations (LTP A2A-EGFP MSNs ¼ 129.7% " 2.4% vs. No LTP A2A-EGFP MSNs ¼ 84.4% " 2.2%, Student t test, ***p ! .001). CTRL, control; dMSN, direct
pathway MSN; EGFP, enhanced green ﬂuorescent protein; EPSP, excitatory postsynaptic potential; HFS, high-frequency stimulation; LTP, long-term potentiation;
MSN, medium spiny neuron; WT, wild-type.
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absent in naïve Ras-GRF1 mutants, we suggest that a L-DOPA-
dependent mechanism occurs in this subset of MSNs after DA
denervation that may bypass the Ras-GRF1 requirement. However,
although this LTP phenomenon may be relevant for the restora-
tion of motor functions in response to L-DOPA, it is unlikely to be
associated with the changes in dyskinesia because depotentiation
appears to be the most crucial synaptic process involved in LID (7).
Finally, another surprising aspect of dopaminergic transmis-
sion was revealed after denervation and induction of LID. In
marked contrast to the naïve condition, depotentiation in both
indirect pathway and direct pathway MSNs of L-DOPA-treated
slices is facilitated in the absence of Ras-GRF1, despite the overall
lower ERK activation found in these mice (22). The idea that ERK
signaling in slices from dyskinetic animals occludes rather than
permits depotentiation in most MSNs was independently con-
ﬁrmed by direct MAPK inhibition in WT dyskinetic slices treated
with U0126. The contrast between MSNs from naïve mice and
MSNs from L-DOPA-treated mice may be in the altered activity of
cytoplasmic or nuclear targets that could affect ERK requirement.
It is conceivable that in dyskinetic animals, the abnormal hyper-
activation of ERK may saturate LTP and may also block its reversal.
In any case, our data support the idea that synaptic depot-
entiation in naïve slices and synaptic depotentiation in L-DOPA-
treated slices are distinct synaptic processes.
In conclusion, the data obtained from the L-DOPA-treated Ras-
GRF1 KO slices could suggest that, in contrast to the naïve
condition, ERK signaling is not required for this form of LTP.
However, further investigation using the MEK inhibitor U0126
revealed a much more complex scenario. We found that ERK
signaling is required to elicit LTP in dyskinetic mice, but only in
"50% of the cells. Unexpectedly, this segregation is not pathway
dependent because it occurs in an apparently stochastic manner in
both striatonigral and striatopallidal MSNs. All-or-none synaptic
plasticity may occur in the CA3-CA1 hippocampal pathway, in
which it appears that the initial synaptic state controls the
behavior of individual synapses (35,36). At the signaling level,
it has been suggested that the ERK cascade may be a bistable
system governed by both positive and negative feedback loops
(37,38). In addition, ERK signaling may be subjected to oscillatory
behavior, as observed in some cellular systems (39). Little is known
about these ERK regulatory processes in the brain and speciﬁcally
in the MSNs of the striatum. However, without providing direct
data to support the hypothesis, we speculate that ERK oscillations
may exist in the brain and that these oscillations may be enhanced
in DA-depleted animals treated with pulsatile L-DOPA, either in
amplitude or in frequency, also altering the intrinsic oscillatory
behavior of MSNs (40,41). The effect of HFS on synaptic activity in a
DA-depleted condition may depend on the temporal integration
between the administration of L-DOPA and the oscillatory state
involving ERK signaling. Also, in patients treated with L-DOPA, the
so-called wearing-off phenomenon has been described as highly
associated with rapid changes in DA levels, although these
changes may not be related to dyskinesia itself but rather to other
aspects of the L-DOPA treatment (42–44). Whether alterations in
the neurotransmitter availability in the striatum may also result in
altered oscillations of ERK activity remains to be demonstrated, but
it is an interesting possibility to be investigated in the future.
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